|
|
|
03.06.26 - 08:06
|
Coolbrook Appoints Veli-Matti Mattila as Chairman to Support the Next Phase of Industrial Scale-Up (Business Wire)
|
|
|
HELSINKI, Finland--(BUSINESS WIRE)--Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has appointed renowned Finnish business leader Veli-Matti Mattila as Chairman of the Board effective immediately.
Mattila brings decades of international leadership experience and board expertise to support Coolbrook's next phase of commercial growth, industrial execution, and global scale-up.
Veli-Matti Mattila is one of Finland's most experienced technology business leaders, having served as CEO of Elisa Corporation from 2003 to 2024, following a long international career at Ericsson, where he held several senior leadership roles, including President of Ericsson Finland and COO & Deputy Head of Market Unit, Nordic & Baltic. He also spent four years in the U.S. and a period of time in Switzerland during his stint at Ericsson. He currently serves as Chairman of Orion Corporation and Enento Group, and has previously chaired Confederation of Finnish Indus...
|
|
|
02.06.26 - 12:51
|
Bioretec Ltd - Manager′s transactions - Jordy Winters (PR Newswire)
|
|
|
TAMPERE, Finland, June 2, 2026 /PRNewswire/ -- Bioretec Oy Company release 2 June 2026 at 13:25 p.m. EEST Bioretec Oy - Managers' Transactions Person subject to the notification requirement Name: Jordy Winters Position: Other senior manager Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13......
|
|
|
02.06.26 - 12:30
|
Bioretec Ltd – Manager′s transactions – Jordy Winters (Cision)
|
|
|
Bioretec Oy Company release 2 June 2026 at 13:25 p.m. EEST
Bioretec Oy - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Jordy Winters
Position: Other senior manager
Issuer: Bioretec Oy
LEI: 7437008736AG7HY51K13
Notification type: INITIAL NOTIFICATION
Reference number: 158959/6/4
____________________________________________
Transaction date: 2026-05-29
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000480454
Nature of transaction:...
|
|
|
|
|
|
|
|
|
01.06.26 - 18:06
|
The Board of Directors of Bioretec Ltd resolved on a new stock option plan (Cision)
|
|
|
Bioretec Ltd Company Announcement 1 June 2026 at 19:05 p.m. EEST
THE BOARD OF DIRECTORS OF BIORETEC LTD RESOLVED ON A NEW STOCK OPTION PLAN
The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group's key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to...
|
|
|
|
|
|
|
|
|
|
|
|
|
18.05.26 - 12:48
|
Bioretec Ltd - Managers′ transactions - Paavola (Cision)
|
|
|
Bioretec Ltd Company Release 18 May 2026 at 1:45 p.m. EEST
Bioretec Oy - Managers' Transactions
____________________________________________
Person subject to the notification requirement
Name: Tuukka Paavola
Position: Chief Financial Officer
Issuer: Bioretec Oy
LEI: 7437008736AG7HY51K13
Notification type: INITIAL NOTIFICATION
Reference number: 157184/4/4
____________________________________________
Transaction date: 2026-05-18
Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)
Instrument type: SHARE
ISIN: FI4000480454
Nature of transaction:...
|
|
|
|
|
|
|
|
|
|
|
13.05.26 - 13:01
|
Bioretec clarifies its 2026–2028 financial target regarding the sales margin (Cision)
|
|
|
Bioretec Ltd Company release 13 May 2026 at 14:00 p.m. EEST
Bioretec clarifies its 2026–2028 financial target regarding the sales margin
To be aligned with industry reporting standards, Bioretec will transition to reporting an adjusted sales margin from Q1/2026 onwards, as compared to the previously reported sales margin. The adjusted sales margin describes the profitability of implant sales before commercialization-related expenses, such as sales commissions. This change improves the transparency of Bioretec's performance in its core business and ensures alignment with industry...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
